REACH, PATHOS and SIRIO: indications for managing atherothrombosis

Submitted: 2 May 2013
Accepted: 2 May 2013
Published: 3 May 2013
Abstract Views: 818
PDF: 1627
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

BACKGROUND Atherothrombosis includes a broad spectrum of clinical manifestations (coronary artery disease, cerebrovascular disease and peripheral artery disease) and is associated with the main causes of morbility and mortality on a world-wide scale. Thus far, most of the available information on atherothrombosis has been derived especially from randomized clinical trials (RCTs). Due to their strict inclusion and exclusion criteria, RCTs not always provide an accurate view of the entire spectrum of atherosclerotic clinical syndromes and are not fully representative of the real-world situation. Recently, three important observational clinical studies performed in unselected populations (REACH, PATHOS, SIRIO) have described the demographic characteristics, risk profiles, management and prognosis of a very large cohort of patients suffering from atherothrombosis.
AIM OF THE STUDY In this article we focus on the description of the main results of REACH, PATHOS and SIRIO studies and we discuss about their relevance in the daily clinical practice.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Imberti, D., Giorgi Pierfranceschi, M., Sverzellati, E., & Orlando, S. (2013). REACH, PATHOS and SIRIO: indications for managing atherothrombosis. Italian Journal of Medicine, 2(2), 35–40. https://doi.org/10.4081/itjm.2008.2.35

Similar Articles

You may also start an advanced similarity search for this article.